417 related articles for article (PubMed ID: 17589519)
1. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
Goga A; Yang D; Tward AD; Morgan DO; Bishop JM
Nat Med; 2007 Jul; 13(7):820-7. PubMed ID: 17589519
[TBL] [Abstract][Full Text] [Related]
2. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
5. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.
Ng SB; Selvarajan V; Huang G; Zhou J; Feldman AL; Law M; Kwong YL; Shimizu N; Kagami Y; Aozasa K; Salto-Tellez M; Chng WJ
J Pathol; 2011 Mar; 223(4):496-510. PubMed ID: 21294123
[TBL] [Abstract][Full Text] [Related]
6. CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.
Huskey NE; Guo T; Evason KJ; Momcilovic O; Pardo D; Creasman KJ; Judson RL; Blelloch R; Oakes SA; Hebrok M; Goga A
Stem Cell Reports; 2015 Mar; 4(3):374-89. PubMed ID: 25733019
[TBL] [Abstract][Full Text] [Related]
7. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.
Sharma K; Patel YC; Srikant CB
Mol Endocrinol; 1996 Dec; 10(12):1688-96. PubMed ID: 8961277
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
9. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels.
D'Agnano I; Valentini A; Fornari C; Bucci B; Starace G; Felsani A; Citro G
Oncogene; 2001 May; 20(22):2814-25. PubMed ID: 11420693
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.
Braun K; Hölzl G; Soucek T; Geisen C; Möröy T; Hengstschläger M
Oncogene; 1998 Oct; 17(17):2259-69. PubMed ID: 9811456
[TBL] [Abstract][Full Text] [Related]
11. Increased p27Kip1 cyclin-dependent kinase inhibitor gene expression following anti-IgM treatment promotes apoptosis of WEHI 231 B cells.
Wu M; Bellas RE; Shen J; Yang W; Sonenshein GE
J Immunol; 1999 Dec; 163(12):6530-5. PubMed ID: 10586045
[TBL] [Abstract][Full Text] [Related]
12. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.
Vlach J; Hennecke S; Alevizopoulos K; Conti D; Amati B
EMBO J; 1996 Dec; 15(23):6595-604. PubMed ID: 8978686
[TBL] [Abstract][Full Text] [Related]
13. Regulation of p27Kip1 accumulation in murine B-lymphoma cells: role of c-Myc and calcium.
Donjerković D; Zhang L; Scott DW
Cell Growth Differ; 1999 Oct; 10(10):695-704. PubMed ID: 10547073
[TBL] [Abstract][Full Text] [Related]
14. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
15. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
18. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
19. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
20. Survivin and escaping in therapy-induced cellular senescence.
Wang Q; Wu PC; Roberson RS; Luk BV; Ivanova I; Chu E; Wu DY
Int J Cancer; 2011 Apr; 128(7):1546-58. PubMed ID: 20503268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
